Coordinatore | CENTRE D'EXCELLENCE EN TECHNOLOGIES DE L'INFORMATION ET DE LA COMMUNICATION
Organization address
city: Charleroi contact info |
Nazionalità Coordinatore | Belgium [BE] |
Totale costo | 3˙276˙699 € |
EC contributo | 2˙495˙024 € |
Programma | FP7-ICT
Specific Programme "Cooperation": Information and communication technologies |
Code Call | FP7-ICT-2009-4 |
Funding Scheme | CP |
Anno di inizio | 2010 |
Periodo (anno-mese-giorno) | 2010-03-01 - 2013-02-28 |
# | ||||
---|---|---|---|---|
1 |
CENTRE D'EXCELLENCE EN TECHNOLOGIES DE L'INFORMATION ET DE LA COMMUNICATION
Organization address
city: Charleroi contact info |
BE (Charleroi) | coordinator | 0.00 |
2 |
Cambridge University Hospitals NHS Foundation Trust
Organization address
address: Hills Rd contact info |
UK (Cambridge) | participant | 0.00 |
3 |
CONSIGLIO NAZIONALE DELLE RICERCHE
Organization address
address: PIAZZALE ALDO MORO contact info |
IT (ROMA) | participant | 0.00 |
4 |
GOTTFRIED WILHELM LEIBNIZ UNIVERSITAET HANNOVER
Organization address
address: Welfengarten contact info |
DE (HANNOVER) | participant | 0.00 |
5 |
INSTITUTE OF COMMUNICATION AND COMPUTER SYSTEMS
Organization address
address: Patission Str. contact info |
EL (ATHINA) | participant | 0.00 |
6 |
LIETUVOS SVEIKATOS MOKSLU UNIVERSITETAS
Organization address
address: A MICKEVICIAUS GATVE contact info |
LT (KAUNAS) | participant | 0.00 |
7 |
NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS
Organization address
address: CHRISTOU LADA contact info |
EL (ATHENS) | participant | 0.00 |
8 |
STRATEGIC MEDICINE BV - SMI
Organization address
address: JOHAN VAN OLDENBARNEVELTLAAN contact info |
NL (DEN HAAG) | participant | 0.00 |
9 |
TECHNISCHE UNIVERSITAET DRESDEN
Organization address
address: HELMHOLTZSTRASSE contact info |
DE (DRESDEN) | participant | 0.00 |
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Clinical trials are increasingly considered to be not only a means for evaluating the effectiveness of new medicine and pharmaceutical formulas but also for experimenting on existing drugs and their appliance to new diseases and disorders. Pharmaceutical companies tend to prefer launching modified versions of existing drugs, which generate generous profits while carrying little risk of rejection. Translation into clinical therapy has to overcome substantial barriers at the preclinical and clinical levels. Thus, bridging basic science to clinical practice comprises a new scientific challenge which can result in successful clinical applications with low financial cost. In the aforementioned context, the results yielding from clinical trials, which are testing the effectiveness of existing drugs and pharmaceutical formulas on diseases other than the ones they are currently treating, are closely dependent on the available data and the patients. The efficacy of such trials requires the pursuit of a number of aspects that need to be addressed ranging from the aggregation of data from various heterogeneous distributed sources (such as electronic health records - EHRs) to the intelligent processing of this data based on the clinical trial-specific requirements for choosing the appropriate patients eligible for recruitment. Within this framework, PONTE aims at providing a platform following a Service Oriented Architecture (SOA) approach that will offer intelligent automatic identification of individuals eligible (concerning their safety and clinical trial efficacy) to participate in clinical trials, as these will be designed and planned through a flexible authoring tool, enabling semantic interoperability of clinical care information systems with clinical research information systems and drug and disease knowledge databases, as well as the appliance of advanced data mining techniques and enhanced learning algorithms.